Cat. No.: HY-12687

Tizoxanide

(Synonyms: TIZ)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Tizoxanide (TIZ) is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. Tizoxanide (TIZ) has anti-HIV-1 activities and potent inhibition of both HBV and HCV replication with values EC₅₀ of 0.46μM and 0.15 μM, respectively. Tizoxanide also exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and suppressing of the activation of the NF-κB and the MAPK signaling pathways in LPS-treated macrophage cells.

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 173903-47-4
Formula: C₁₀H₇N₃O₄S
Molecular Weight:265.25

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tizoxanide Chemical Structure

CAS No.: 173903-47-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

HIV-1

All HIV Isoforms :

All Parasite Isoforms :

All IKK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	29.8 μM Compound: TIZ	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay	[PMID: 34055214]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 2	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	[PMID: 21553812]
HepG2 2.2.15	EC₅₀	0.15 μM Compound: 2	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA measured 24 hrs after last dose Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA measured 24 hrs after last dose	[PMID: 21553812]
HepG2 2.2.15	EC₅₀	0.46 μM Compound: 2	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA measured 24 hrs after last dose Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA measured 24 hrs after last dose	[PMID: 21553812]
Huh-7	CC₅₀	14 μM Compound: 2	Cytotoxicity against human Huh7.5 cells after 3 days by neutral red dye assay Cytotoxicity against human Huh7.5 cells after 3 days by neutral red dye assay	[PMID: 22059983]
Vero	CC₅₀	388 μM Compound: TIZ	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 21397502]
Vero	CC₅₀	388 μM Compound: Tizoxanide	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 25801157]

In Vitro

Tizoxanide (TIZ) induces mild mitochondrial uncoupling and activate AMPK in hepatocytes^[1].
Tizoxanide (TIZ) inhibits hepatitis C virus (HCV) replication in HCV replicon systems^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HepG2 cells
Concentration:

1-25 µmol/L
Incubation Time:

24 h
Result:

Induced mitochondrial uncoupling and AMPK activation not due to the non-specific cytotoxicity in HepG2 cells at concentrations less than 25 µmol/L.

Immunofluorescence^[1]

Cell Line:

HepG2 cells
Concentration:

10 µmol/L
Incubation Time:

24 h
Result:

Promoted the nuclear translocation of TFEB by activating AMPK in HepG2 cells.

RT-PCR^[1]

Cell Line:

HepG2 cells
Concentration:

1-25 µmol/L
Incubation Time:

24 h
Result:

Induced the increase transcription of SQSTM1/P62 in HepG2 cells.

Western Blot Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

1-25 µmol/L
Incubation Time:

24 h
Result:

Activated AMPK and increased phosphorylation of ACC in HepG2 cells.

Cell Cytotoxicity Assay^[3]

Cell Line:

RP7 cells, NTZ-11 and TIZ-9 cell lines
Concentration:

The initial drug concentration was 0.02 µM, followed by 0.05, 0.1, 0.5, and 1 µM, and subsequent weekly increases of 1 µM until a final concentration of 11 µM.
Incubation Time:

3 days
Result:

Againsted HCV replication in RP7 cells (IC₅₀: 0.16), NTZ-11 (IC₅₀:1.2) and TIZ-9 cell lines (IC₅₀: 1.5)

In Vivo

Tizoxanide (TIZ) (10 mg/kg; i.v.) can pass the BBB and distribute to the brain tissue. Tizoxanide retains in brain is obviously longer than that in plasma^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley rats^[2]
Dosage:

10 mg/kg
Administration:

Tizoxanide (10 mg/kg; i.v.)
Result:

Could pass the BBB and distribute to the brain tissue.

Chemical Information

CAS No. 173903-47-4
Appearance Solid
Molecular Weight 265.25
Formula C₁₀H₇N₃O₄S
Color White to yellow
SMILES

O=C(NC1=NC=C([N+]([O-])=O)S1)C2=CC=CC=C2O
Synonyms

TIZ
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (13)

All

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Nitazoxanide protects against heart failure with preserved ejection and metabolic syndrome induced by high-fat diet (HFD) plus L-NAME "two-hit" in mice. [Abstract]

2025 Mar;15(3):1397-1414. PMID: 40370562
Acta Pharm Sin B

The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan. [Abstract]

2024 Jul;14(7):3266-3280. PMID: 39027239
Acta Pharm Sin B

Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice. [Abstract]

2022 Mar;12(3):1322-1338. PMID: 35530137
EBioMedicine

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2. [Abstract]

2022 Aug;82:104148. PMID: 35834886
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Br J Pharmacol

Repurposing nitazoxanide as a novel anti-atherosclerotic drug based on mitochondrial uncoupling mechanisms. [Abstract]

2023 Jan;180(1):62-79. PMID: 36082580
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Biochem Pharmacol

The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice. [Abstract]

2024 Jun:224:116205. PMID: 38615918
Chem Biol Interact

Nitazoxanide protects against experimental ulcerative colitis through improving intestinal barrier and inhibiting inflammation. [Abstract]

2024 May 25:395:111013. PMID: 38663798
Virology

Inhibition of vaccinia virus replication by nitazoxanide. [Abstract]

2018 May:518:398-405. PMID: 29625403
Biomed Chromatogr

Analysis of tizoxanide, active metabolite of nitazoxanide, in rat brain tissue and plasma by UHPLC-MS/MS. [Abstract]

2020 Feb;34(2):e4716. PMID: 31633824
Research Square Preprint

2021 Aug.
SSRN

2021 Feb 2.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (94.25 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : < 1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7700 mL

18.8501 mL

37.7003 mL

5 mM

0.7540 mL

3.7700 mL

7.5401 mL

10 mM

0.3770 mL

1.8850 mL

3.7700 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 5 mg/mL (18.85 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

Protocol 2

Add each solvent one by one: 17% Solutol HS-15 in Saline

Solubility: 5 mg/mL (18.85 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Fengfeng Li, et al. Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice. Acta Pharm Sin B. 2022 Mar;12(3):1322-1338. [Content Brief]

[2]. Sixun Guo, et al. Analysis of tizoxanide, active metabolite of nitazoxanide, in rat brain tissue and plasma by UHPLC-MS/MS. Biomed Chromatogr. 2020 Feb;34(2):e4716. [Content Brief]

[3]. Brent E Korba, et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. [Content Brief]

[4]. Brent E Korba, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. [Content Brief]

[5]. Jiaoqin Shou, et al. Tizoxanide Inhibits Inflammation in LPS-Activated RAW264.7 Macrophages via the Suppression of NF-κB and MAPK Activation. Inflammation. 2019 Aug;42(4):1336-1349. [Content Brief]

[6]. Korba BE, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008 Jan;77(1):56-63. [Content Brief]

[7]. Korba BE, et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. [Content Brief]

[8]. Ashton LV, et al. In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide. Vet Med Int. 2010 Aug 12;2010. pii: 891010. [Content Brief]

[9]. Trabattoni D, et al. Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication. Sci Rep. 2016 Jun 2;6:27148. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7700 mL	18.8501 mL	37.7003 mL	94.2507 mL
	5 mM	0.7540 mL	3.7700 mL	7.5401 mL	18.8501 mL
	10 mM	0.3770 mL	1.8850 mL	3.7700 mL	9.4251 mL
	15 mM	0.2513 mL	1.2567 mL	2.5134 mL	6.2834 mL
	20 mM	0.1885 mL	0.9425 mL	1.8850 mL	4.7125 mL
	25 mM	0.1508 mL	0.7540 mL	1.5080 mL	3.7700 mL
	30 mM	0.1257 mL	0.6283 mL	1.2567 mL	3.1417 mL
	40 mM	0.0943 mL	0.4713 mL	0.9425 mL	2.3563 mL
	50 mM	0.0754 mL	0.3770 mL	0.7540 mL	1.8850 mL
	60 mM	0.0628 mL	0.3142 mL	0.6283 mL	1.5708 mL
	80 mM	0.0471 mL	0.2356 mL	0.4713 mL	1.1781 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Tizoxanide

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Liver Cancer Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Lactylation Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Tizoxanide

All HIV Isoforms

All Parasite Isoforms

All IKK Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tizoxanide Related Classifications

Cat. No.: HY-12687